Edwards Lifesciences (EW) Tops Q4 EPS by 4c, Offers Guidance

Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.59, $0.04 better than the analyst estimate of $0.55. Revenue for the quarter came in at $1.39 billion versus the consensus estimate of $1.36 billion.

GUIDANCE:

Edwards Lifesciences sees Q1 2025 EPS of $0.58-$0.64, versus the consensus of $0.59. Edwards Lifesciences sees Q1 2025 revenue of $1.35-1.43 billion, versus the consensus of $1.36 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• NeuroSense posts narrower H1 loss, targets Canada drug filing by December
• KLX Energy narrows Q3 2026 revenue guidance, completes rights offering